Abstract
The MTB-DR-RIF 9G membrane can detect by detecting multiple mutations in multiple codons. The MTB-DR-RIF 9G membrane possesses clinical applicability in point-of-care settings for the following reasons: (i) 100% similar results with that of the sequencing analysis for clinical samples, (ii) discrimination of the multiple mutations in multiple codons, (iii) a specific/non-specific hybridization ratio higher than 350:1, and (iv) the sensitivity was found to be 1-10 copies/test for detection and discrimination of the wild and mutant TB strains. Graphical abstract Schematic illustration of the effect of controller DNA on the hybridization of the immobilized probes (corresponding to the wild TB strain) with the PCR product of (a) wild TB strain and (b) mutant TB strain.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
